The Goldman Sachs Group Inc. Rating Affirmed At 'AA-/A-1+'; Outlook Stable Aug 07

  • ID: 1783451
  • August 2007
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Aug. 13, 2007--Standard & Poor's Ratings Services' said today that it affirmed its 'AA-/A-1+' counterparty credit rating on The Goldman Sachs Group Inc. (Goldman) following the company's announcement that it, along with other parties, will make an equity investment of $3 billion into Global Equity Opportunities fund (GEO). The outlook is stable. GEO is a long/short quantitative strategy fund that is part of the alternative asset platform of Goldman Sachs Asset Management (GSAM). Goldman has disclosed that the fund has been particularly affected by recent market turmoil, with its net asset value being off about 30% last week. Goldman has stated that it views the fund as representing a good investment at this time, given...

Companies mentioned in this report are:
- The Goldman Sachs Group Inc.

Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- The Goldman Sachs Group Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.